An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

ATTRUBY®

Drug Information Related Patent

Hold Company

BRIDGEBIO PHARMA

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 356MG BASE

Indication

Attruby® is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

Use

Instructions for Use

API

ACORAMIDIS HYDROCHLORIDE

API Structure

We Supply

ACORAMIDIS

Drug Patent

Patent No	Expiration Date
10398681	2031/5/5
10513497	2038/2/16
10842777	2031/5/5
11058668	2039/3/22
11260047	2039/8/16
11919865	2038/2/16
12005043	2039/8/16
12070449	2039/3/22
8877795	2031/5/5
9169214	2031/5/5
9642838	2031/5/5
9913826	2031/5/5

API Patent

Patent No	Expiration Date
10513497	2038/2/16
11919865	2038/2/16

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION